Capmatinib
Capmatinib is a targeted pill for the small group of lung cancers driven by a MET exon 14 skipping mutation, found by tumour sequencing.
Overview
Capmatinib is an oral MET inhibitor for metastatic non-small cell lung cancer whose tumours carry a MET exon 14 skipping mutation, present in roughly 3 to 4 percent of lung adenocarcinomas. In the GEOMETRY mono-1 trial it produced responses in most untreated patients and in a smaller share of previously treated ones. The FDA granted accelerated approval in 2020. NICE did not complete its appraisal, so it is not routinely funded in England. Peripheral oedema and nausea are the common side effects.
A selective, ATP-competitive inhibitor of the MET receptor kinase; tumours with MET exon 14 skipping mutations keep the receptor switched on, and blocking it shuts down the growth signal. Connects to MET.
1.Capmatinib slips into a pocket on MET.
- Appraised for
- Advanced NSCLC with MET exon 14 skipping
- Notes
- Terminated appraisal published 3 May 2023: NICE stopped the appraisal, so capmatinib is not routinely funded in England. FDA accelerated approval (Tabrecta) since 2020.
Sources: NICE TA884. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2020 | Metastatic NSCLC with a MET exon 14 skipping mutation (accelerated approval) |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Capmatinib" OR ABSTRACT:"Capmatinib" OR TITLE:"Tabrecta" OR ABSTRACT:"Tabrecta" OR TITLE:"INC280" OR ABSTRACT:"INC280") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Capmatinib, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentCeritinib
Shares Novartis, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- TreatmentBrigatinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- TreatmentDacomitinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- TreatmentMobocertinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- TreatmentTaletrectinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- TreatmentEnsartinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- TreatmentSunvozertinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- TreatmentRuxolitinib
Shares Novartis, Small-molecule kinase inhibitors and the tag gap-fill.